Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-24. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
James Hibberd who commented for The Hollywood Reporter said that the trailer showed Homelander becoming more unstable after an apparent breakdown and also commenting over how the trailer also introduced a new formula that can turn anybody into a superhero for 24 hours, for which he complemented that Butcher might finally get the opportunity to be on the level of his nemesis and face him. Digital Spy's Shaun Wren deemed the trailer to be "packed with new heroes, gruesome scenes and a proper introduction to Jensen Ackles' original superhero Soldier Boy", and was excited to see the new developments that have taken during the time jump from the second to third season.
Stauromedusae, small sessile cnidarians with stalks and no medusa stage, have traditionally been classified as members of the Scyphozoa, but recent research suggests they should be regarded as a separate class, Staurozoa. The Myxozoa, microscopic parasites, were first classified as protozoans. Research then found that Polypodium hydriforme, a non-myxozoan parasite within the egg cells of sturgeon, is closely related to the Myxozoa and suggested that both Polypodium and the Myxozoa were intermediate between cnidarians and bilaterian animals. More recent research demonstrates that the previous identification of bilaterian genes reflected contamination of the myxozoan samples by material from their host organism, and they are now firmly identified as heavily derived cnidarians, and more closely related to Hydrozoa and Scyphozoa than to Anthozoa. Some researchers classify the extinct conulariids as cnidarians, while others propose that they form a completely separate phylum. Current classification according to the World Register of Marine Species:
=== Dreamcast port === On February 14, 2000, Sierra announced that a port of Half-Life for the Dreamcast console was in development by Captivation Digital Laboratories with Valve and Gearbox Software. It would feature improvements including higher-polygon character models and new lighting effects. Gearbox, who had developed Opposing Force, created a new single-player campaign for the port, Half-Life: Blue Shift, focusing on the security guard Barney. The port was delayed to September 2000, then November, when game publications began to receive early copies for review. Reception was mixed, with criticism for the inconsistent frame rate, long loading times and lack of online play. Sierra planned to release a version with online multiplayer using SegaNet. The Gearbox CEO, Randy Pitchford, said he suggested adding multiplayer modes and mods from the Windows version, including Team Fortress Classic and the multiplayer modes from Opposing Force. Sierra delayed the port again and said they hoped to finish development that year. On March 29, 2001, Sierra announced that Blue Shift would be released for Windows along with the character models developed for the Dreamcast version, as part of the Half-Life High Definition Pack. On June 16, 2001, four days after the release of Blue Shift, Sierra announced that it had canceled the Dreamcast port, citing "changing market conditions". It was weeks away from its release date and virtually complete. In 2013, a late version of the Dreamcast port leaked online, featuring complete versions of Half-Life and Blue Shift.
==== Soil water ==== The isotopic composition of soil is controlled by the input of precipitation. Therefore, the δD of soil is similar to that of local precipitation. However, due to evaporation, soil tends to be more D-enriched than precipitation. The degree of enrichment varies greatly depending on atmospheric humidity, local temperature as well as the depth of the soil beneath the surface. According to the study by Meinzer et al. (1999), as the depth in the soil increases, the δD of soil water decreases.
== Adenosine triphosphate == ATP is the only type of usable form of chemical energy for musculoskeletal activity. It is stored in most cells, particularly in muscle cells. Other forms of chemical energy, such as those available from oxygen and food, must be transformed into ATP before they can be utilized by the muscle cells.
Sources: en.wikipedia.org
A very private individual, Gaddafi was given to rumination and solitude and could be reclusive. Gaddafi described himself as a "simple revolutionary" and "pious Muslim" called upon by God to continue Nasser's work. Gaddafi was an austere and devout Muslim, although, according to Vandewalle, his interpretation of Islam was "deeply personal and idiosyncratic". He was also a football enthusiast and enjoyed both playing that game and horse-riding as a means of recreation. He regarded himself as an intellectual; he was a fan of Beethoven and said his favourite novels were Uncle Tom's Cabin, Roots, and The Outsider. Gaddafi considered personal appearance important; Blundy and Lycett described him as "extraordinarily vain". Gaddafi had a large wardrobe, and sometimes changed his outfit more than once a day. He favoured either a military uniform or traditional Libyan dress, tending to eschew Western-style suits. He saw himself as a fashion icon, stating "Whatever I wear becomes a fad. I wear a certain shirt and suddenly everyone is wearing it." After his ascension to power, Gaddafi moved to the Bab al-Azizia barracks, a 6-square-kilometre (2.3 square miles) fortified compound, 3.2 kilometres (2 miles) from the centre of Tripoli. In the 1980s, his lifestyle was considered modest in comparison to those of many other Arab leaders. He was preoccupied with his own security, regularly changing where he slept and sometimes grounding all other planes in Libya when he was flying. He made particular requests when travelling to foreign countries.
==== Genetically modified organisms (GMOs) ==== Golden rice was a GMO created in 2005 through heterologous expression as a humanitarian effort to address the effects of Vitamin A deficiency. Oryza sativa rice was transfected with a gene to produce β-carotene, a Vitamin A precursor that has a yellow-orange color.
== Randomised controlled trial (RCT) == The AIDA diabetes simulator has been tested out in a pilot randomised controlled trial (RCT). The protocol used for the RCT was described a priori in the medical / diabetes literature. The study sought to assess whether diabetes educational teaching sessions using the AIDA simulator led to better outcomes than similar diabetes educational teaching sessions without a computer. The study was run at the Ospedale di Marino, near Rome, in Italy by an independent diabetologist / endocrinologist – unconnected with the simulator's development. Twenty-four volunteers (12 male and 12 female) with type 1 diabetes of more than 6-years duration, aged 19–48 years, who gave written informed consent, were randomly assigned to one of two study groups, each receiving different teaching interventions. Group A was exposed to the AIDA diabetes simulator, while Group B (the control group) received conventional lessons with slides and transparencies. Six lessons were held for each group (one per week). At the beginning and end of the study all subjects had their glycated hemoglobin (HbA1c) measured. The subjects also carefully documented the incidence of any symptomatic hypoglycaemic episodes ('hypos'), whether mild (sweating, dizziness), moderate (nausea, vomiting), or severe (requiring assistance). The results seem encouraging. HbA1c levels in Group A dropped significantly from 7.2% to 6.4% after lessons with the diabetes simulator (p = 0.01).
=== Early history === More than two thousand years ago the Scythians lived on the banks of the river Don. Many Scythian tombs have been found in this area. Subsequently, the area was inhabited by the Khazars and the Polovtsians. From the 16th to the 18th centuries the steppes of the Don River were part of "the Wild Field" (Russian: Дикое Поле). In the late Middle Ages the area was under the general control of the Golden Horde, and numerous Tatar (especially Crimean Tatar) armed groups roamed there, attacking and enslaving merchants and settlers. The first Christians to settle on the territories around the Don were the Jassi and Kosogi tribes of the Khazar Kaghanate of the 7th to 10th centuries. After the fall of the Golden Horde in 1480, more colonists started to expand onto this land from the Novgorod Republic after the Battle of Shelon (1471), and from the neighboring Principality of Ryazan. Until the end of the 16th century, the Don Cossacks inhabited independent free territories.
This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with a disulfide as acceptor. The systematic name of this enzyme class is glutathione:homocystine oxidoreductase. This enzyme participates in methionine metabolism and glutathione metabolism.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.